Pierre Fabre`s Ebvallo (tabelecleucel) Receives Approval in Europe
Pierre Fabre`s Ebvallo (Tabelecleucel) Approved In Europe
Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)
Atara Biotherapeutics Ebvallo (tabelecleucel) Receives Approval in Europe
Atara`s Ebvallo (tabelecleucel) Receives Approval in Europe
The dream of an “off-the-shelf” T-cell therapy has become a reality, courtesy of the allogeneic aficionados over at Atara Biotherapeutics.
THOUSAND OAKS, Calif. & CASTRES, France--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA) and Pierre Fabre today announced that the European Commission (EC) has granted marketing authorization for Ebvallo™ (tabelecleucel) as a monotherapy for the treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein?Barr virus positive post?transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.
Imbrium Therapeutics Presents Results of a Phase 2 Study of Sunobinop at 33rd American Academy of Addiction Psychiatry Annual Meeting
Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting